Bdenza 40 mg Capsules contain Enzalutamide, a potent androgen‑receptor inhibitor used to treat castration‑resistant prostate cancer by blocking androgen signaling and slowing tumor progression.
Bdenza (Enzalutamide) is an oral antiandrogen indicated for the treatment of:
Metastatic castration‑resistant prostate cancer (mCRPC), both pre‑ and post‑chemotherapy
Non‑metastatic castration‑resistant prostate cancer (nmCRPC) to delay metastasis
It works by inhibiting androgen‑receptor nuclear translocation, DNA binding, and co‑activator recruitment, thereby reducing prostate tumor cell growth and improving survival.
Uses of Bdenza 40 mg Capsules:
mCRPC (pre‑chemotherapy): Improves radiographic progression‑free and overall survival.
mCRPC (post‑chemotherapy): Offers survival benefit after docetaxel failure.
nmCRPC: Delays onset of metastasis and prolongs metastasis‑free survival.
mHSPC (off‑label): Used with androgen‑deprivation therapy in hormone‑sensitive disease.
Biochemical recurrence (investigational): For rising PSA post‑local therapy.
Combination regimens (off‑label): Being evaluated with novel hormonal agents or immunotherapies.
Storage Instructions:
Store at 20 °C to 25 °C (room temperature).
Protect from light and moisture.
Keep in the original container with desiccant.
Do not freeze.
Keep out of reach of children.
How Bdenza Works (Mechanism of Action):
Enzalutamide is a potent androgen‑receptor inhibitor that:
Prevents androgen binding to the receptor
Inhibits receptor nuclear translocation
Blocks DNA binding and co‑activator recruitment
This triple blockade disrupts androgen‑driven gene transcription, induces apoptosis, and reduces prostate tumor growth.
Side Effects:
Common:
Fatigue
Hot flashes
Headache
Hypertension
Diarrhea
Arthralgia
Severe (Rare):
Seizures – Monitor in patients with predisposing factors
